Loading
Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Ibrutinib during induction and as maintenance should be part of first-line treatment for younger patients with mantle cell lymphoma; whether transplant adds anything to an ibrutinib-containing regimen is still being followed.
ZUMA-2 gave patients with BTK-inhibitor-refractory mantle cell lymphoma, who previously had a median survival under a year, a therapy with durable remissions in a substantial fraction. Brexu-cel is now standard after BTK inhibitor failure and CAR-T is being tested earlier in the disease. Neurotoxicity rates are higher than in other lymphoma CAR-T trials.
Query for this cancer: (TITLE:"Mantle cell lymphoma" OR ABSTRACT:"Mantle cell lymphoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Mantle cell lymphoma, not a curated reading list.
Mantle cell lymphoma recognised as a distinct entity (REAL classification 1994).
68% response in relapsed MCL; the first indication for any BTK inhibitor.
First CAR-T for MCL: 93% response after BTKi failure.
Ibrutinib replaces transplant in fit patients; acalabrutinib + BR improves PFS first line in older patients.